Abstract
D-2-hydroxyglutaric aciduria type II (D2HGA2) is a severe inborn disorder of metabolism caused by heterozygous R140 mutations in the IDH2 (isocitrate dehydrogenase 2) gene. Here we report the results of treatment of two children with D2HGA2, one of whom exhibited severe dilated cardiomyopathy, with the selective mutant IDH2 enzyme inhibitor enasidenib. In both children, enasidenib treatment led to normalization of D-2-hydroxyglutarate (D-2-HG) concentrations in body fluids. At doses of 50 mg and 60 mg per day, no side effects were observed, except for asymptomatic hyperbilirubinemia. For the child with cardiomyopathy, chronic D-2-HG inhibition was associated with improved cardiac function, and for both children, therapy was associated with improved daily functioning, global motility and social interactions. Treatment of the child with cardiomyopathy led to therapy-coordinated changes in serum phospholipid levels, which were partly recapitulated in cultured fibroblasts, associated with complex effects on lipid and redox-related gene pathways. These findings indicate that targeted inhibition of a mutant enzyme can partly reverse the pathology of a chronic neurometabolic genetic disorder.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
Data from this clinical trial are available from the authors and can be requested by completing the data request form for Gustave Roussy clinical trials at https://redcap.gustaveroussy.fr/redcap/surveys/?s=DYDTLPE4AM. The trial steering committee and the sponsor will review the requests on a case-by-case basis. A specific agreement between the sponsor and the researcher may be required before data transfer.
References
Kranendijk, M. et al. IDH2 mutations in patients with d-2-hydroxyglutaric aciduria. Science 330, 336 (2010).
Kranendijk, M., Struys, E. A., Salomons, G. S., Van der Knaap, M. S. & Jakobs, C. Progress in understanding 2-hydroxyglutaric acidurias. J. Inherit. Metab. Dis. 35, 571–587 (2012).
Chalmers, R. A. et al. D-2-hydroxyglutaric aciduria: case report and biochemical studies. J. Inherit. Metab. Dis. 3, 11–15 (1980).
Tommasini-Ghelfi, S. et al. Cancer-associated mutation and beyond: the emerging biology of isocitrate dehydrogenases in human disease. Sci. Adv. 5, eaaw4543 (2019).
Ward, P. S. et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17, 225–234 (2010).
Figueroa, M. E. et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18, 553–567 (2010).
Chowdhury, R. et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep. 12, 463–469 (2011).
Abelson, S. et al. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature 559, 400–404 (2018).
Desai, P. et al. Somatic mutations precede acute myeloid leukemia years before diagnosis. Nat. Med. 24, 1015–1023 (2018).
Stein, E. M. et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 130, 722–731 (2017).
Yen, K. et al. AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations. Cancer Discov. 7, 478–493 (2017).
Wang, F. et al. A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D-2-hydroxyglutaric aciduria type II mouse model. J. Inherit. Metab. Dis. 39, 807–820 (2016).
Akbay, E. A. et al. D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes Dev. 28, 479–490 (2014).
Bautista, F. et al. Phase I or II study of ribociclib in combination with topotecan-temozolomide or everolimus in children with advanced malignancies: arms A and B of the AcSé-ESMART trial. J. Clin. Oncol. 39, 3546–3560 (2021).
Nishina, T. et al. Interleukin-11-expressing fibroblasts have a unique gene signature correlated with poor prognosis of colorectal cancer. Nat. Commun. 12, 2281 (2021).
Maity, P. et al. Persistent JunB activation in fibroblasts disrupts stem cell niche interactions enforcing skin aging. Cell Rep. 36, 109634 (2021).
Karlstaedt, A. et al. Oncometabolite d-2-hydroxyglutarate impairs α-ketoglutarate dehydrogenase and contractile function in rodent heart. Proc. Natl Acad. Sci. USA 113, 10436–10441 (2016).
Badur, M. G. et al. Oncogenic R132 IDH1 mutations limit NADPH for de novo lipogenesis through (D)2-hydroxyglutarate production in fibrosarcoma cells. Cell Rep. 25, 1018–1026 (2018).
Ruiz, M. et al. Lipidomics unveils lipid dyshomeostasis and low circulating plasmalogens as biomarkers in a monogenic mitochondrial disorder. JCI Insight 4, e123231 (2019).
Alessenko, A. V. & Albi, E. Exploring sphingolipid implications in neurodegeneration. Front. Neurol. 11, 437 (2020).
Morscher, R. J. et al. First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial. Eur. J. Cancer 157, 268–277 (2021).
Pasqualini, C. et al. Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium. Eur. J. Cancer 150, 53–62 (2021).
Paoletti, X. et al. A comparative analysis of paediatric dose-finding trials of molecularly targeted agent with adults’ trials. Eur. J. Cancer 49, 2392–2402 (2013).
Sparrow, S. S. in Encyclopedia of Clinical Neuropsychology (eds Kreutzer, J. S. et al.) 2618–2621 (Springer, 2011).
Poinsignon, V. et al. Quantitation of isocitrate dehydrogenase (IDH)-induced D and L enantiomers of 2-hydroxyglutaric acid in biological fluids by a fully validated liquid tandem mass spectrometry method, suitable for clinical applications. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 1022, 290–297 (2016).
Folch, J., Lees, M. & Sloane Stanley, G. H. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 226, 497–509 (1957).
Shillito, B. et al. Lipidome variations of deep-sea vent shrimps according to acclimation pressure: a homeoviscous response? Deep Sea Res. 1 Oceanogr. Res. Pap. 161, 103285 (2020).
Escobar, J. et al. Development of a reliable method based on ultra-performance liquid chromatography coupled to tandem mass spectrometry to measure thiol-associated oxidative stress in whole blood samples. J. Pharm. Biomed. Anal. 123, 104–112 (2016).
Acknowledgements
We thank N. Garcia (Hôpital Robert Debré, Paris, France) for initial care and discussions on the patients; M. David, L. Delestre, P. Dessen (UMR INSERM U1170) and D. Farabos (Saint Antoine Hospital) for excellent technical assistance; A. Boutron and E. Lebigot (Hôpital Bicêtre, Le Kremlin Bicêtre, France) for providing primary fibroblasts; P. Rustin (UMR1141, Paris, France), G. Pierron (Gustave Roussy) and R. J. Morscher (Kinderspital Zurich, Switzerland) for discussions; A. Paci and J. Delahousse (Gustave Roussy) for 2-HG analysis; the team of the clinical research direction and statistics department at Gustave Roussy for sponsoring and running the AcSé-ESMART trial; and Celgene Corporation/Bristol Myers Squibb for providing the study drug and financial grant. The work is generated, in part, by members of the European Reference Network for Hereditary Metabolic Disorders (MetabERN). We are grateful to M. Touat and R. Maki for critical reading of the paper. AcSé-ESMART is supported by grants from the Institut National du Cancer (INCa) within the AcSé program, the Association Imagine for Margo, Fondation ARC and Celgene Corporation/Bristol Myers Squibb France. B.G. is supported by the ‘Parrainage médecin-chercheur’ of Gustave Roussy. N.D. is supported by the Swedish State Support for Clinical Research (ALFGBG-965049 and ALF-GBG-967240). The work was supported by the Paris Île-de-France Region under the ‘DIM Thérapie génique’ initiative (C.O., C.P. and A.L.). The funders had no role in study design, data collection and analysis, preparation of the manuscript or decision to publish.
Author information
Authors and Affiliations
Contributions
B.G., M. Schiff., V.P.-L., N.D., S.D., C.O. and S.D.B. conceived the study, designed and conducted the experiments, provided and analyzed the data and wrote the paper. S.-M.S., C.D., A.L., A.D., C.P. and P.B. designed and conducted the experiments and analyzed the data. K.Y., M. Su and D.S. developed the study treatment. All authors approved the paper.
Corresponding author
Ethics declarations
Competing interests
D.S. is a current board member at Agios Pharmaceuticals and a current shareholder of Agios Pharmaceuticals. The other authors declare no competing interests.
Peer review
Peer review information
Nature Medicine thanks Anja Karlstaedt, Julie-Aurore Losman, Ross Levine and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editor: Michael Basson, in collaboration with the Nature Medicine team.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Extended data
Extended Data Fig. 1 Height and weight of patient 1 (a) and patient 2 (b).
Dots mark height and weight at indicated biological age in relevant growth charts for boys and girls respectively; green shaded area depicts enasidenib treatment duration since aged 7.1 years and 8.0 years, respectively.
Extended Data Fig. 2 Lipids that responded to therapy in serum of patient 1.
Phospholipid species included phosphatidylcholine (PC; a) and phosphatidylethanolamine (PE; b) plasmalogens as well as sphingomyelins (SM; c). Molecules are designated by the sums of acyl and alkyl residues (www.lipidmaps.org/data/classification/lipid_cns.html). For example, PC O-38:5 refers to several molecular species, notably PC O-18:0/20:5, PC O-16:0/22:5 and/or PC O-18:1/20:4.
Extended Data Fig. 3 Lipids showing significant patterns in serum, investigated in cultured fibroblasts (patient 1).
Lipids showing significant patterns in serum, investigated in cultured fibroblasts in patient 1. The lipids that were found to be associated with therapy (Fig. 2a and Extended Data Fig. 2a–c) were tested for differential enrichment in patient 1 fibroblasts at 1, 3 and 6 days of culture in the presence of mutant IDH2 inhibitor or vehicle. The lipids with statistically significant differences between inhibitor and vehicle conditions (two-sided t-test on log transformed data, p < 0.05) at one or more of the three time points of culture were as follows: PC 35:4, PC O36-3,PC O36-4, PE O36:3 (higher values for vehicle than inhibitor), and Sm d18:1/20:0, Sm d18:1/22:0,Sm d18:1/24:0, Sm d18:1/24:1, Sm d18:1/24:2 (higher values for inhibitor than vehicle). For readability purposes data are presented as mean values without standard deviations, except for phosphatidylserine, because of the complex kinetics shown by the large number of metabolites of all other subclasses. The number of biological replicates was 3 per condition (treatment and time of culture).
Extended Data Fig. 4 Metabolite levels in patient 1 cultured fibroblasts.
Metabolite levels in patient 1 fibroblasts cultured for 1-6 days in the presence of mutant IDH2 inhibitor relative to vehicle mean value from the corresponding time point (set to 100%, highlighted by a horizontal dotted line). a, 2-hydroxyglutaric acid (total levels); b, citric acid; c, oxidized/reduced glutathione ratio; d, 2-oxoglutaric acid. Two-sided t-test of inhibitor/vehicle ratios on log-transformed values (a,b,d) and on inhibitor/vehicle ratios from paired samples for the GSSG/GSH ratio (c); NS = statistically not significant (p > 0.05). Y-axis log-scaled except for the GSSG/GSH ratio. Data are presented as mean values +/− standard deviation. The data points represent the values of biological replicates from the inhibitor condition (N = 3 biological samples) relative to the ratio between the inhibitor and the control mean values (a,b,d) or to the mean of individual vehicle/control ratios from paired samples (c).
Extended Data Fig. 5 Patient 1 fibroblast transcriptome.
a. Transcript levels of selected genes of microarrays from patient 1 and control fibroblasts cultured for 3 days in the presence of mutant IDH2 inhibitor or vehicle (see Methods). Y-axis: fold-intensities are relative to the mean of control values in the vehicle condition (%). Transcript levels of 8 major antioxidant defense enzymes. NS = statistically not significant (two-sided t-test; p > 0.05). b, Transcript levels of 4 major enzymes involved in lipogenesis or fatty acid beta-oxidation. The large color bars show the mean values (blue for inhibitor, red for vehicle) and error bars show the standard error of mean (N = 3 biological replicates per condition). Two-sided t-test p-values are shown over horizontal thin bars that compare patient 1 and control fibroblasts (vehicle condition), or inhibitor and vehicle, for patient 1; NS: not significant (p > 0.05). c,d, The published fibroblast IL11-related 20 gene signature15 and e,f, an extended 192 gene signature (including the published signature) from our reanalysis of the same study are compared to our fibroblast transcriptomes by GSEA with default settings (see Methods). Of these lists, probes for 19 out of 20, and 173 out of 192 genes, respectively, were present in our dataset. In all 4 panels, the nominal GSEA p-value is 0. c, Published fibroblast IL11-associated gene shortlist is enriched in patient relative to control fibroblasts. d, Published fibroblast IL11-associated gene signature is suppressed by the inhibitor in patient fibroblasts. e, Extended IL11-negative cell gene list (N = 85 genes) is significantly induced by the inhibitor (two-sided t-test; p < 0.05). f, Extended IL11-positive cell gene list (N = 88 genes) is significantly suppressed by the inhibitor.
Supplementary information
Supplementary Information
Supplementary Table 1: Main clinical milestones before and on enasidenib treatment in patient 1 and patient 2. Supplementary Table 2: Serum lipidomic data for patient 1. Supplementary Table 3: Lipidomic data from patient 1 fibroblasts. Supplementary Table 4: Gene pathway enrichment data corresponding to Fig. 2c.
Supplementary Video 1
Left: Before treatment start, patient needed manual support and encouragement from her father to walk 436 m. Top-right: After 6 months of enasidenib treatment, she walked 390 m independently without manual support next to parent. Lower-right: After 12 months, she walked 424 m completely unaided.
Supplementary Video 2
Left: Before treatment start, patient walked down stairs with two-handed support. Top-right: After 6 months of enasidenib treatment, she walked down stairs with one-handed support in 12.0 s. Lower-right: After 12 months, she walked down stairs with one-handed support in 10.9 s.
Supplementary Video 3
Left: Before treatment start, patient was unable to walk on a line. Top-right: After 6 months of enasidenib treatment, she was able to walk a short distance following a line on the floor. Lower-right: After 12 months, she was able to walk following a line and on tip-toe.
Supplementary Video 4
Left: Before treatment start, BOT-2 test: 4 points. Top-right: After 6 months of enasidenib treatment, BOT-2 test: 13 points. Patient used a better pen grip when drawing and had begun to imitate a circle and words, and her movements became more fluent and precise. Lower-right: After 12 months, BOT-2 test: 19 points. Drawing and imitating a circle and words and movements became more fluent and precise.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Geoerger, B., Schiff, M., Penard-Lacronique, V. et al. Enasidenib treatment in two individuals with D-2-hydroxyglutaric aciduria carrying a germline IDH2 mutation. Nat Med 29, 1358–1363 (2023). https://doi.org/10.1038/s41591-023-02382-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-023-02382-9
This article is cited by
-
AcSé-ESMART, a European precision cancer medicine proof-of-concept platform trial
Nature Medicine (2023)